Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

P. Dô · SciRah

Researcher profile · Semantic Scholar

P. Dô

Share profile

P. Dô — researcher profile on SciRah

h-index: 19
Works: 54
Citations: 1,428

Most-cited papers

Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial.
A. Scherpereel, J. Mazières, L. Greillier, S. Lantuejoul +20 more
2019The Lancet Oncology396 citations Open access
Semantic Scholar
Feasibility and clinical impact of re-biopsy in advanced non small-cell lung cancer: a prospective multicenter study in a real-world setting (GFPC study 12-01).
C. Chouaid, C. Dujon, P. Dô, I. Monnet +14 more
2014Lung Cancer179 citations
Semantic Scholar
Harmonizing SUVs in multicentre trials when using different generation PET systems: prospective validation in non-small cell lung cancer patients
C. Lasnon, C. Desmonts, E. Quak, R. Gervais +3 more
2013European Journal of Nuclear Medicine and Molecular Imaging128 citations Open access
Semantic Scholar
BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers
S. Couraud, P. Souquet, C. Paris, P. Dô +17 more
2015European Respiratory Journal79 citations Open access
Semantic Scholar
Second- or third-line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Results of the IFCT-1501 MAPS2 randomized phase II trial
A. Scherpereel, J. Mazières, L. Greillier, P. Dô +14 more
201758 citations
Semantic Scholar
18F-FDG PET/CT heterogeneity quantification through textural features in the era of harmonisation programs: a focus on lung cancer
C. Lasnon, M. Majdoub, B. Lavigne, P. Dô +4 more
2016European Journal of Nuclear Medicine and Molecular Imaging54 citations
Semantic Scholar
Generating harmonized SUV within the EANM EARL accreditation program: software approach versus EARL-compliant reconstruction
C. Lasnon, Thibault Salomon, C. Desmonts, P. Dô +3 more
2017Annals of Nuclear Medicine46 citations
Semantic Scholar
Safety of combined PD‐1 pathway inhibition and radiation therapy for non‐small‐cell lung cancer: A multicentric retrospective study from the GFPC
P. Lesueur, A. Escande, J. Thariat, E. Vauléon +8 more
2018Cancer Medicine42 citations Open access
Semantic Scholar
Outcome of EGFR-mutated NSCLC patients with MET-driven resistance to EGFR tyrosine kinase inhibitors
S. Baldacci, J. Mazières, P. Tomasini, N. Girard +14 more
2017OncoTarget35 citations Open access
Semantic Scholar
Cost‐Effectiveness Analysis of Afatinib versus Gefitinib for First‐Line Treatment of Advanced EGFR‐Mutated Advanced Non–Small Cell Lung Cancers
C. Chouaid, L. Luciani, K. Lelay, P. Dô +5 more
2017Journal of Thoracic Oncology34 citations Open access
Semantic Scholar
Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer
Benjamin Houdu, C. Lasnon, I. Licaj, G. Thomas +4 more
2018European Journal of Nuclear Medicine and Molecular Imaging33 citations
Semantic Scholar
Cost-utility analysis of maintenance therapy with gemcitabine or erlotinib vs observation with predefined second-line treatment after cisplatin–gemcitabine induction chemotherapy for advanced NSCLC: IFCT-GFPC 0502-Eco phase III study
I. Borget, M. Pérol, D. Pérol, A. Lavolé +15 more
2012BMC Cancer32 citations Open access
Semantic Scholar
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study).
R. Descourt, M. Pérol, G. Rousseau-Bussac, D. Planchard +11 more
2019Lung Cancer30 citations Open access
Semantic Scholar
Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non-small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria.
L. Gandhi, S. Ou, A. Shaw, F. Barlesi +14 more
2017European Journal of Cancer28 citations
Semantic Scholar
PACSA: Phase II study of pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC).
J. Guigay, J. Fayette, C. Even, D. Cupissol +14 more
201628 citations
Semantic Scholar
Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E-Mutant NSCLC in Real-World Setting: GFPC 01-2019
J. Auliac, S. Bayle, P. Dô, Gwenaëlle Le Garff +9 more
2020Cancers27 citations Open access
Semantic Scholar
Economic Analysis of First‐Line Treatment with Erlotinib in an EGFR‐Mutated Population with Advanced NSCLC
A. Vergnenègre, B. Massutí, F. de Marinis, E. Carcereny +6 more
2016Journal of Thoracic Oncology25 citations Open access
Semantic Scholar
Association between lung cancer somatic mutations and occupational exposure in never-smokers
C. Paris, P. Dô, B. Mastroianni, A. Dixmier +15 more
2017European Respiratory Journal24 citations Open access
Semantic Scholar
Utility of serum anti‐cetuximab immunoglobulin E levels to identify patients at a high risk of severe hypersensitivity reaction to cetuximab
B. Dupont, D. Mariotte, A. Dugué, B. Clarisse +17 more
2017British Journal of Clinical Pharmacology21 citations Open access
Semantic Scholar
Non-Small Cell Lung Cancer Patients Harboring HER2 Mutations: Clinical Characteristics and Management in a Real-Life Setting. Cohort HER2 EXPLORE GFPC 02–14
J. Auliac, P. Dô, S. Bayle, H. Doubre +6 more
2019Advances in Therapy19 citations Open access
Semantic Scholar
Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting.
M. Sassier, A. Dugué, B. Clarisse, P. Lesueur +17 more
2015Lung Cancer19 citations
Semantic Scholar
Second/third-line nivolumab vs nivo plus ipilimumab in malignant pleural mesothelioma: Long-term results of IFCT-1501 MAPS2 phase IIR trial with a focus on hyperprogression (HPD)
G. Zalcman, J. Mazières, L. Greillier, S. Brosseau +16 more
2019Annals of Oncology16 citations Open access
Semantic Scholar
LBA58_PRSecond or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial
G. Zalcman, J. Mazières, L. Greillier, S. Lantuejoul +15 more
201716 citations Open access
Semantic Scholar
Off-Label Use of Crizotinib as a Neoadjuvant Treatment for a Young Patient When Conventional Chemotherapy Gave No Benefits in Stage IIIA Non-Small Cell Lung Cancer
D. Dumont, P. Dô, D. Lerouge, G. Planchard +4 more
2017The American journal of case reports13 citations Open access
Semantic Scholar
Identification of I1171N resistance mutation in ALK-positive non-small-cell lung cancer tumor sample and circulating tumor DNA.
Alison C. Johnson, P. Dô, N. Richard, C. Dubos +3 more
2016Lung Cancer9 citations
Semantic Scholar
Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study
R. Descourt, M. Pérol, G. Rousseau-Bussac, D. Planchard +13 more
2022Cancers8 citations Open access
Semantic Scholar
Real-life experience of ceritinib in crizotinib-pretreated ALK+ advanced non-small cell lung cancer patients
J. Cadranel, A. Cortot, H. Léna, B. Mennecier +16 more
2018ERJ Open Research7 citations Open access
Semantic Scholar
IFCT-GFPC-1101 trial: A multicenter phase III assessing a maintenance strategy determined by response to induction chemotherapy compared to continuation maintenance with pemetrexed in patients (pts) with advanced non-squamous (NSQ) NSCLC.
M. Pérol, C. Audigier-Valette, O. Molinier, A. Cortot +17 more
20174 citations
Semantic Scholar
1200P BrigALK2 study: A multicentric real-world study evaluating brigatinib in ALK positive advanced pre-treated non-small cell lung cancers: Long-term follow-up with focus on lorlatinib efficacy after brigatinib
R. Descourt, M. Pérol, G. Rousseau-Bussac, D. Planchard +12 more
2021Annals of Oncology3 citations Open access
Semantic Scholar
Management and outcomes of non–small cell lung cancer patients with rapid progression under second‐or‐more‐line immune checkpoint inhibitors: ERORECI study (GFPC 2016‐04)
A. Vergnenègre, M. Geier, F. Guisier, R. Lamy +10 more
2019Cancer Medicine3 citations Open access
Semantic Scholar
Impact of KRAS G12C mutation on the efficacy of chemoradiotherapy in patients with unresectable stage II or III non-small cell lung cancer
J. Cabon, D. Lerouge, S. Thureau, Jacques Balosso +17 more
2025Frontiers in Oncology2 citations Open access
Semantic Scholar
1392P Brigatinib in patients with ALK-positive advanced non-small cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)
R. Descourt, M. Pérol, D. Planchard, G. Rousseau-Bussac +12 more
20202 citations Open access
Semantic Scholar
3105 Dose optimization of rociletinib for EGFR mutated NSCLC: Benefit/risk analysis from the TIGER-X trial
J. Soria, J. Goldman, H. Wakelee, S. Gadgeel +16 more
20152 citations
Semantic Scholar
[Malignant mesothelioma and constitutional BAP1 gene mutations].
Z. Neviere, P. Berthet, F. Polycarpe, C. Dubos-Arvis +2 more
2019Revue des maladies respiratoires1 citations Open access
Semantic Scholar
Correction to: Why harmonization is needed when using FDG PET/CT as a prognosticator: demonstration with EARL-compliant SUV as an independent prognostic factor in lung cancer
Benjamin Houdu, C. Lasnon, I. Licaj, G. Thomas +4 more
2018European Journal of Nuclear Medicine and Molecular Imaging1 citations Open access
Semantic Scholar
Oxaliplatin-induced bronchiolitis obliterans organizing pneumonia following hyperthermic intraperitoneal chemotherapy.
G. Le Baut, J. Guilloit, V. Leprince, Y. Ollivier +5 more
2018Journal of Gastrointestinal Oncology1 citations Open access
Semantic Scholar
P3.02b-051 Outcome of Advanced EGFR-Mutated NSCLC Patients with MET-Driven Acquired Resistance to EGFR TKI. Results of the METEORE Study: Topic: EGFR Clinical
S. Baldacci, J. Mazières, P. Tomasini, N. Girard +13 more
20171 citations Open access
Semantic Scholar
A phase II study assessing the benefit of cisplatin re-introduction (stop and go strategy) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): The IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer).
F. Barlesi, J. Raimbourg, P. Dô, P. Dumont +12 more
20161 citations
Semantic Scholar
Efficacité et tolérance cérébrale d’une chimiothérapie par platine/pemetrexed/bévacizumab chez des patients atteints de carcinome bronchique non à petites cellules (CBNPC) non épidermoïde
S. Deshayes, G. Robinet, G. Picart, V. Avrillon +5 more
20200 citations
Semantic Scholar
P2.14-65 Efficacy of Dabrafenib Plus Trametinib Combination in Patients with BRAF V600E–Mutant NSCLC in Real World Setting
J. Auliac, S. Bayle, P. Dô, G. Legarff +10 more
2019Journal of Thoracic Oncology0 citations Open access
Semantic Scholar
Efficacy of Dabrafenib plus Trametinib plus trametinib combinationin patients with BRAF V600E-mutant NSCLC in real word setting
J. Auliac, S. Bayle, P. Dô, G. Legarff +10 more
20190 citations
Semantic Scholar
Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer)
J. Bennouna, F. Barlesi, P. Dô, P. Dumont +9 more
2018ESMO Open0 citations Open access
Semantic Scholar
P1.04-35 Quick Progression (QP) in Patients Treated by Nivolumab (IO) in 2nd Line or More for Non-Small Cell Lung Cancer: ERORECI Study (GFPC 2016-04)
A. Vergnenègre, M. Geier, F. Guisier, R. Lamy +10 more
2018Journal of Thoracic Oncology0 citations Open access
Semantic Scholar
Tolérance et efficacité de la combinaison d’anti PD-1 et de radiothérapie chez les patients atteints de cancer bronchique non à petites cellules métastatiques : étude rétrospective multicentrique
P. Lesueur, A. Escande, J. Thariat, I. Monnet +8 more
2018Cancer Radiothérapie0 citations
Semantic Scholar
Poster SessionP3.02b-064 Time to EGFR-TKI Treatment for Patients with Advanced NSCLC and EGFR Activating Mutation in a Tertiary Cancer Center: Topic: EGFR Clinical
J. Le Guévelou, A. Dugué, N. Richard, C. Dubos +6 more
20170 citations Open access
Semantic Scholar
P3.02b-127 NSCLC Patients Harboring HER2 Mutation: Clinical Characteristics and Management in Real World Setting. EXPLORE GFPC 02-14: Topic: EGFR RES
J. Auliac, P. Dô, S. Bayle, H. Doubre +6 more
20170 citations Open access
Semantic Scholar
P1.07-008 Lomustine Endoxan VP16 as Second or Further Line for Recurrent or Progressive Brain Metastases from SCLC: Topic: Drug Treatment Alone and in Combination with Radiotherapy
C. Naltet, A. Dugué, C. Dubos, P. Dô +4 more
20170 citations Open access
Semantic Scholar
P3.03-001 Immunotherapy Toxicity: Are General Practitioner Satisfied About Information Transmitted? A Retrospective Survey
L. Senecal, F. Divanon, N. Leiber, C. D. Arvis +2 more
20170 citations Open access
Semantic Scholar
P3.02b-013 Evaluation of Lung Specific GPA Score in Adenocarcinoma Patients with Brain Metastasis and EGFR Activating Mutation: Topic: EGFR Biomarkers
W. Kao, A. Dugué, P. Dô, C. Dubos +4 more
20170 citations Open access
Semantic Scholar
Non small cell lung cancer (NSCLC) patients harboring BRAF mutation: Clinical characteristics and management in real world setting. Cohort BRAF EXPLORE GFPC 02-14
J. Auliac, S. Bayle, A. Vergnenègre, G. Fraboulet +10 more
20160 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

F. Guisier×14
Invite
F. Guisier — researcher profile on SciRah
C. Chouaid×14
Invite
C. Chouaid — researcher profile on SciRah
I. Monnet×13
Invite
I. Monnet — researcher profile on SciRah
R. Gervais×12
Invite
R. Gervais — researcher profile on SciRah

×11

Invite

J. Auliac — researcher profile on SciRah

Invite

M. Pérol — researcher profile on SciRah

D. Moro-Sibilot×10

Invite

D. Moro-Sibilot — researcher profile on SciRah

Invite

A. Cortot — researcher profile on SciRah

L. Falchero×10

Invite

L. Falchero — researcher profile on SciRah

Invite

É. Dansin — researcher profile on SciRah

J. Mazières×8

Invite

J. Mazières — researcher profile on SciRah

D. Planchard×8

Invite

D. Planchard — researcher profile on SciRah